查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
大腸癌症市場:KOL的洞察
市場調查報告書
商品編碼
1815992

大腸癌症市場:KOL的洞察

KOL Insight - Colorectal Cancer
出版日期: | 出版商: FirstWord Group | 英文 | 商品交期: 最快1-2個工作天內

價格
簡介目錄

本報告深入分析了不斷發展的結直腸癌治療格局，重點關注標靶治療、免疫治療和精準醫療的整合。報告借鑒北美和歐洲關鍵意見領袖的觀點，探討了當前的臨床實踐、分子分析的影響以及 HER2 抑制劑和 KRAS 抑制劑等新型藥物的應用。

報告也回顧了有前景的在研藥物、關鍵臨床試驗以及液體活檢和 ctDNA 等診斷工具的進展，幫助醫藥專業人士深入了解轉移性結直腸癌 (mCRC) 管理的新興趨勢、課題和機遇。

關鍵問題解答

  • 1.臨床醫生如何使用和看待目前的結直腸癌標靶治療？
  • 2.預期哪一類藥物將對未來轉移性大腸直腸癌 (mCRC) 的處方趨勢產生最大影響？
  • 3.哪些產品線最有前景？它們的潛在市場影響是什麼？
  • 4.哪些臨床試驗有可能改變大腸直腸癌的未來治療？
  • 5.轉移性大腸直腸癌的診斷預計將如何發展？
  • 6.轉移性大腸直腸癌治療面臨的主要課題和機會是什麼？

主要品牌

  • ABBV-400（替利妥珠單抗/阿迪替康）
  • 阿瓦斯汀（貝伐單抗）
  • BOT/BAL（博替利單抗/巴替利單抗）
  • Braftovi（恩考拉非尼）
  • Cyramza（雷莫蘆單抗）
  • Enfertu（曲妥珠單抗/德魯替康）
  • 愛必妥（西妥昔單抗）
  • Eth Lumadenant（Arcus Biosciences）
  • Fluzakura（呋喹替尼）
  • GDC-6036（givalasib）
  • 花崗岩
  • Hetronifly/漢斯壯 (seruplimab)
  • 伊波奈昔單抗
  • Gemperli（多斯塔利單抗）
  • Keytruda（派姆單抗）
  • Clazati（阿達格拉西布）
  • Lumacras (sotorasib)
  • 穆薩斯托繼
  • 腫瘤疫苗
  • Opdivo/Yervoy（納武單抗/伊普利姆瑪）
  • PRO 140（leronlimab）
  • RMC-98051/RMC-6236
  • 自由人(阿米凡他單抗)
  • Stivarga (瑞戈非尼)
  • Tuxa (圖卡替尼)
  • Bactosertib
  • Vectibix (帕尼單抗)
  • XL 092 (贊札林替尼)
  • Zaltrap (齊柏西普)
  • Zihera (贊達馬單抗)

研究方法：

"治療趨勢" 報告透過與全球領先的關鍵意見領袖 (KOL) 進行深入訪談，探討關鍵疾病領域的當前和未來治療前景。 KOL 的篩選標準非常嚴格，包括全球知名度、臨床專業知識以及在其治療領域的影響力。每次訪談都配有精心設計的討論指南。這些指南由我們與 KOL 合作制定，並由行業專家進行同行評審，以確保問題全面且與當前市場動態相關。每份報告發布後，我們會持續 12 個月進行市場監測，及時提供關鍵意見領袖 (KOL) 的最新資訊，涵蓋重要新聞事件、市場變化和市場發展。

我們的報告有何特別之處？

FirstWord Reports 是值得信賴的行業領導者，專注於製藥業，為生物製藥專業人士和決策者提供深入、可操作的洞察。我們深厚的行業知識使我們能夠提供相關且有價值的洞察，幫助客戶掌握新興趨勢，有​​效應對複雜課題。憑藉廣泛的研究以及來自領先專家和關鍵意見領袖的獨立、公正的見解，我們的報告能夠提供您所需的準確性和可靠性。獨家存取獨家訪談和數據，以及持續的市場監測，確保您能夠全面了解市場動態。我們的報告涵蓋 40 多個動態疾病領域，並提供醫生情報，包括 KOL 洞察和定量醫生調查，以及行業專家對醫療事務、數位健康、銷售和行銷、市場准入和其他領域問題的看法，使您能夠做出更明智的數據驅動決策，並在快速變化的行業中保持競爭力。

簡介目錄

This report offers an in-depth analysis of the evolving treatment landscape for colorectal cancer, focusing on targeted therapies, immunotherapies, and the integration of precision medicine. Drawing on perspectives from key opinion leaders in North America and Europe, it examines current clinical practices, the impact of molecular profiling, and the adoption of novel agents such as HER2 and KRAS inhibitors.

This report also reviews promising pipeline drugs, pivotal clinical trials, and advances in diagnostic tools like liquid biopsy and ctDNA, providing pharmaceutical professionals with a detailed understanding of emerging trends, challenges, and opportunities in mCRC management.

Key Questions Answered:

  • 1. How are current targeted therapies for colorectal cancer used and perceived by clinicians?
  • 2. Which drug classes are expected to most impact future prescribing trends in mCRC?
  • 3. What are the most promising pipeline products and their potential market impact?
  • 4. Which clinical trials could change future treatment practices in colorectal cancer?
  • 5. How is the diagnosis of metastatic colorectal cancer expected to evolve?
  • 6. What are the major challenges and opportunities in the mCRC treatment landscape?

Key Brands:

  • ABBV-400 (telisotuzumab adizutecan)
  • Avastin (bevacizumab)
  • BOT/BAL (botensilimab/balstilimab)
  • Braftovi (encorafenib)
  • Cyramza (ramucirumab)
  • Enhertu (trastuzumab deruxtecan)
  • Erbitux (cetuximab)
  • Etrumadenant (Arcus Biosciences)
  • Fruzaqla (fruquintinib)
  • GDC-6036 (divarasib)
  • GRANITE
  • Hetronifly/Hansizhuang (serplulimab)
  • Ivonescimab
  • Jemperli (dostarlimab)
  • Keytruda (pembrolizumab)
  • Krazati (adagrasib)
  • Lumakras (sotorasib)
  • Muzastotug
  • OncoVAX
  • Opdivo/Yervoy (nivolumab/iplimumab)
  • PRO 140 (leronlimab)
  • RMC-98051/RMC-6236
  • Rybrevant (amivantamab)
  • Stivarga (regorafenib)
  • Tukysa (tucatinib)
  • Vactosertib
  • Vectibix (panitumumab)
  • XL 092 (zanzalintinib)
  • Zaltrap (ziv-aflibercept)
  • Ziihera (zanidatamab)

Methodology:

Therapy Trend reports are developed through in-depth interviews with the world's foremost Key Opinion Leaders (KOLs) on the current and future treatment landscapes in major disease areas. KOLs are carefully selected based on strict screening criteria, including their global reputation, clinical expertise, and influence within their therapeutic area. Each interview is guided by a meticulously crafted discussion guide. These guides are developed in collaboration with KOLs and peer-reviewed by industry experts to ensure that the questions are comprehensive and pertinent to current market dynamics. Through continuous market monitoring over a 12-month period following the publication of each report, we provide timely updates from KOLs on key news events, market shifts, and clinical developments.

What makes our reports different?

FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.